# Athira Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/athira-pharma

- Industry: Biotechnology
- Headquarters: Bothell, US
- Website: www.athira.com
- Total disclosed funding: $100M
- Latest round: Series B (May 29, 2020)
- Investors on record: 19

## About

Based in Washington, US, and founded in 2011, Athira Pharma, Inc. operates as a biopharmaceutical company dedicated to developing novel small molecule therapeutics aimed at treating neurodegenerative diseases. In September 2020, Athira Pharma, Inc. raised USD 204 million in an IPO, selling 12 million shares at USD 17 per share on the NASDAQ. Further, in January 2021, the firm raised USD 90 million in a public offering by selling 4 million shares at USD 22.5 per share on the NASDAQ..The firm as of May 2024, is led by its President and CEO, Mark Litton.

The company targets the neurotrophic hepatocyte growth factor (HGF) system to promote neuronal regeneration, provide neuroprotection, and potentially modify the progression of diseases such as Alzheimer’s, Parkinson’s, and ALS. Athira's product pipeline includes several promising candidates, with Fosgonimeton (ATH-1017) being the most advanced. These small molecules are designed to enhance the HGF signaling system, which has shown potential in preclinical studies to reduce inflammation, slow neurodegeneration, and offer neuroprotection.

## Funding rounds

- Series B, May 29, 2020, $89M — Sofinnova Investments, Venrock, Viking Global Investors, RTW Investments, Rock Springs Capital, Franklin Templeton, Perceptive Advisors, Janus Henderson Investors, LifeSci Partners, Surveyor Capital, Sahsen Foundation, Logos Capital, Highside Capital Management, Avidity Partners, Ric and Suzanne Kayne
- Series A, Apr 13, 2017, $1.4M — Dolby Family Ventures, Alzheimer's Drug Discovery Foundation
- Series A, Feb 11, 2016, $10M — WRF Capital, The W Fund

## Investors

- WRF Capital (https://capitalatlas.ai/funds/wrf-capital) — Series A
- The W Fund — Series A
- Dolby Family Ventures (https://capitalatlas.ai/funds/dolby-family-ventures) — Series A
- Alzheimer's Drug Discovery Foundation — Series A
- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series B
- Venrock (https://capitalatlas.ai/funds/venrock) — Series B
- Viking Global Investors (https://capitalatlas.ai/funds/viking-global-investors) — Series B
- RTW Investments (https://capitalatlas.ai/funds/rtw-investments) — Series B
- Rock Springs Capital — Series B
- Franklin Templeton (https://capitalatlas.ai/funds/franklin-templeton) — Series B
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series B
- Janus Henderson Investors — Series B
- LifeSci Partners (https://capitalatlas.ai/funds/lifesci-partners) — Series B
- Surveyor Capital — Series B
- Sahsen Foundation — Series B
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series B
- Highside Capital Management — Series B
- Avidity Partners — Series B
- Ric and Suzanne Kayne — Series B